(2021, July 13). Moleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia: Protocol amendment allows for change in dose limiting toxicity (DLT) criteria for future enrolled subjects. PR Newswire.
Chicago Style (17th ed.) Citation"Moleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia: Protocol Amendment Allows for Change in Dose Limiting Toxicity (DLT) Criteria for Future Enrolled Subjects." PR Newswire 13 Jul. 2021.
MLA (9th ed.) Citation"Moleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia: Protocol Amendment Allows for Change in Dose Limiting Toxicity (DLT) Criteria for Future Enrolled Subjects." PR Newswire, 13 Jul. 2021.